Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patent Foramen Ovale Closure in Stroke and the PASCAL Classification System.

JAMA neurology·2026
Same author

Percutaneous left atrial appendage closure with concomitant dual-device implantation: a single-center observational study.

Frontiers in cardiovascular medicine·2026
Same author

A Cardiologist's Perspective on Patent Foramen Ovale-Associated Conditions.

Cardiology clinics·2024
Same author

Impact of gender in patients with device-related thrombosis after left atrial appendage closure - A sub-analysis from the multicenter EUROC-DRT-registry.

Echocardiography (Mount Kisco, N.Y.)·2024
Same author

Every Patent Foramen Ovale Should Be Closed.

Journal of clinical medicine·2024
Same author

Patent Foramen Ovale Closure in Older Patients With Stroke: Patient Selection for Trial Feasibility.

Neurology·2024

Related Experiment Video

Updated: Feb 22, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

Left atrial appendage occlusion.

Fabian Nietlispach1, Igal Moarof, Maurizio Taramasso

  • 1University Heart Center, University Hospital Zurich, Zurich, Switzerland.

Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
|September 25, 2017
PubMed
Summary
This summary is machine-generated.

Left atrial appendage occlusion (LAAO) offers significant stroke prevention for atrial fibrillation (AF) patients. Younger individuals with high bleeding risk gain the most absolute benefit, warranting discussion of LAAO versus anticoagulation.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.4K

Related Experiment Videos

Last Updated: Feb 22, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.4K

Area of Science:

  • Cardiology
  • Medical Devices
  • Stroke Prevention

Background:

  • Atrial fibrillation (AF) increases stroke risk, necessitating preventative therapies.
  • Left atrial appendage occlusion (LAAO) is a primary treatment for stroke prevention in AF patients.
  • Patients with high bleeding risk, particularly younger ones, show the greatest absolute benefit from LAAO.

Purpose of the Study:

  • To evaluate the absolute and relative risk reduction of stroke with LAAO in AF patients.
  • To compare the benefits of LAAO against lifelong oral anticoagulation.
  • To emphasize shared decision-making for AF stroke prevention strategies.

Main Methods:

  • Analysis of risk reduction data for LAAO in diverse AF patient populations.
  • Comparison of outcomes between LAAO and oral anticoagulation therapies.
  • Review of clinical guidelines and patient profiles for LAAO consideration.

Main Results:

  • LAAO provides the highest absolute risk reduction in younger AF patients with high lifetime bleeding risk.
  • Patients with high bleeding risk or prior bleeding experience the greatest relative risk reduction with LAAO.
  • LAAO is a viable alternative to lifelong oral anticoagulation for stroke prevention in AF.

Conclusions:

  • LAAO should be considered for all AF patients as an alternative to oral anticoagulation.
  • Informed patient decision-making regarding LAAO versus anticoagulation is crucial.
  • Tailoring stroke prevention strategies based on individual bleeding risk is essential for optimal outcomes.